<p>恩安达制药公司（NASDAQ:ENTA - 获取免费报告）的股票在目前覆盖该公司的五家评级机构中获得了 “适度买入” 的共识评级，MarketBeat.com 报道。一位股票研究分析师给予该股票卖出评级，三位分析师给予买入评级，一位分析师给予强烈买入评级。在过去一年中，更新了对该股票覆盖的经纪公司平均一年目标价为 17.25 美元。</p>
<p>获取 <strong>恩安达制药</strong> 的提醒：</p>
<p>几位分析师对该公司进行了评论。JMP Securities 在 2 月 11 日的报告中重申了 “市场表现优于大盘” 的评级，并对恩安达制药的股票设定了 21.00 美元的目标价。HC Wainwright 在 2 月 11 日的报告中重申了 “买入” 评级，并对恩安达制药的股票设定了 18.00 美元的目标价。最后，StockNews.com 在 2 月 19 日的研究报告中将恩安达制药的评级从 “卖出” 上调至 “持有”。</p>
<p><strong>查看我们对 ENTA 的最新分析</strong></p>
<h2>内部活动</h2>
<p>在相关消息中，首席执行官 Jay R. Luly 于 2 月 12 日星期三购买了 45,000 股公司的股票。每股的平均成本为 5.69 美元，总交易额为 256,050.00 美元。收购后，首席执行官现在拥有 846,638 股公司股票，价值 4,817,370.22 美元。这代表了其持股比例的 5.61% 的增长。此次购买已在向 SEC 的备案中披露，您可以通过此链接访问。内部人士持有公司股票的 13.89%。</p>
<h2>机构投资者对恩安达制药的看法</h2>
<p>一些大型投资者最近增加或减少了对该公司的持股。Krensavage Asset Management LLC 在第三季度将其在恩安达制药的持股增加了 19.7%。Krensavage Asset Management LLC 现在拥有 1,498,074 股该生物技术公司的股票，价值 15,520,000 美元，此前在上个季度又收购了 246,736 股。RA Capital Management L.P. 在第四季度购买了恩安达制药的新股份，价值约为 5,968,000 美元。Marshall Wace LLP 在第四季度将其在恩安达制药的持股增加了 9.3%。Marshall Wace LLP 现在拥有 930,087 股该生物技术公司的股票，价值 5,348,000 美元，此前在上个季度又购买了 79,197 股。Millennium Management LLC 在第四季度将其在恩安达制药的持股增加了 22.7%。Millennium Management LLC 现在拥有 896,987 股该生物技术公司的股票，价值 5,158,000 美元，此前在上个季度又购买了 165,692 股。最后，Geode Capital Management LLC 在第三季度将其在恩安达制药的持股增加了 3.1%。Geode Capital Management LLC 现在拥有 477,351 股该生物技术公司的股票，价值 4,946,000 美元，此前在上个季度又购买了 14,575 股。94.99% 的股票由机构投资者和对冲基金持有。</p>
<h2>恩安达制药股票表现</h2>
<p>恩安达制药（NASDAQ:ENTA - 获取免费报告）股票在周五开盘时为 4.73 美元。该公司的市值为 1.0091 亿美元，市盈率为-0.96，贝塔值为 0.47。恩安达制药的 1 年最低价为 4.52 美元，1 年最高价为 17.24 美元。该公司的 50 日移动平均价格为 6.39 美元，200 日移动平均价格为 8.00 美元。</p>
<p>恩安达制药（NASDAQ:ENTA - 获取免费报告）最近于 2 月 10 日星期一发布了季度财报。这家生物技术公司报告的每股收益（EPS）为-1.05 美元，超过了市场共识预期的-1.16 美元，超出幅度为 0.11 美元。恩安达制药的股本回报率为-75.53%，净利润率为-157.57%。整体来看，股票分析师预测恩安达制药在本年度将发布-4.65 的每股收益。</p>
<h2>关于恩安达制药</h2>
<p>（获取免费报告）</p>
<p>恩安达制药公司是一家生物技术公司，专注于发现和开发用于治疗病毒感染和肝病的小分子药物。其产品管线包括 EDP-514，目前正在进行针对慢性乙型肝炎病毒（HBV）感染的 1b 期临床开发；EDP-938 和 EDP-323，目前正在进行针对呼吸道合胞病毒的 II 期临床开发；EDP-235，目前正在进行针对人类冠状病毒的 II 期临床开发；以及 Glecaprevir，目前已上市用于治疗慢性丙型肝炎病毒（HCV）感染。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比恩安达制药更好</li>
<li>安静期到期的解释</li>
<li>Archer Aviation 在非洲的交易可能会提升 ACHR 股票</li>
<li>天然气价格继续上涨，这些股票将受益</li>
<li>空头卖家对这三只半导体股票是否错误？</li>
<li>八月值得购买的三只最佳零售股票</li>
<li>波音在三月份获得 500 亿美元订单——BA 股票现在值得买吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在恩安达制药吗？</h2>
<p>在考虑恩安达制药之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而恩安达制药并不在名单上。</p>
<p>虽然 Enanta 制药目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Enanta制药

<p>Enanta 制药公司（NASDAQ:ENTA）获得了五家券商的 “适度买入” 共识评级。一位分析师将其评级为卖出，三位分析师评级为买入，一位分析师评级为强力买入。平均目标价为 17.25 美元。首席执行官 Jay R. Luly 以每股 5.69 美元购买了 45,000 股，增加了他的持股比例。机构投资者持有 94.99% 的股份。Enanta 的股票开盘价为 4.73 美元，市值为 1.0091 亿美元。该公司报告的季度每股收益为（1.05 美元），超出预期。Enanta 专注于开发针对病毒感染和肝脏疾病的药物</p>

<p>Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received a consensus rating of &#34;Moderate Buy&#34; from the five ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $17.25.</p>
<div class="lb-trans"><p>恩安达制药公司（NASDAQ:ENTA - 获取免费报告）的股票在目前覆盖该公司的五家评级机构中获得了 “适度买入” 的共识评级，MarketBeat.com 报道。一位股票研究分析师给予该股票卖出评级，三位分析师给予买入评级，一位分析师给予强烈买入评级。在过去一年中，更新了对该股票覆盖的经纪公司平均一年目标价为 17.25 美元。</p>
</div><p>Get <strong>Enanta Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>恩安达制药</strong> 的提醒：</p>
</div><p>Several analysts have commented on the company. JMP Securities restated a &#34;market outperform&#34; rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, StockNews.com raised Enanta Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, February 19th.</p>
<div class="lb-trans"><p>几位分析师对该公司进行了评论。JMP Securities 在 2 月 11 日的报告中重申了 “市场表现优于大盘” 的评级，并对恩安达制药的股票设定了 21.00 美元的目标价。HC Wainwright 在 2 月 11 日的报告中重申了 “买入” 评级，并对恩安达制药的股票设定了 18.00 美元的目标价。最后，StockNews.com 在 2 月 19 日的研究报告中将恩安达制药的评级从 “卖出” 上调至 “持有”。</p>
</div><p><strong>View Our Latest Analysis on ENTA</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ENTA 的最新分析</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, CEO Jay R. Luly bought 45,000 shares of the company's stock in a transaction that occurred on Wednesday, February 12th. The shares were acquired at an average cost of $5.69 per share, for a total transaction of $256,050.00. Following the acquisition, the chief executive officer now owns 846,638 shares in the company, valued at $4,817,370.22. This represents a 5.61 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 13.89% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Jay R. Luly 于 2 月 12 日星期三购买了 45,000 股公司的股票。每股的平均成本为 5.69 美元，总交易额为 256,050.00 美元。收购后，首席执行官现在拥有 846,638 股公司股票，价值 4,817,370.22 美元。这代表了其持股比例的 5.61% 的增长。此次购买已在向 SEC 的备案中披露，您可以通过此链接访问。内部人士持有公司股票的 13.89%。</p>
</div><h2>Institutional Investors Weigh In On Enanta Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对恩安达制药的看法</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in the company. Krensavage Asset Management LLC grew its stake in shares of Enanta Pharmaceuticals by 19.7% during the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company's stock valued at $15,520,000 after acquiring an additional 246,736 shares in the last quarter. RA Capital Management L.P. purchased a new stake in Enanta Pharmaceuticals during the 4th quarter worth approximately $5,968,000. Marshall Wace LLP raised its position in shares of Enanta Pharmaceuticals by 9.3% in the 4th quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company's stock valued at $5,348,000 after purchasing an additional 79,197 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Enanta Pharmaceuticals by 22.7% during the 4th quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company's stock valued at $5,158,000 after buying an additional 165,692 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company's stock worth $4,946,000 after buying an additional 14,575 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投资者最近增加或减少了对该公司的持股。Krensavage Asset Management LLC 在第三季度将其在恩安达制药的持股增加了 19.7%。Krensavage Asset Management LLC 现在拥有 1,498,074 股该生物技术公司的股票，价值 15,520,000 美元，此前在上个季度又收购了 246,736 股。RA Capital Management L.P. 在第四季度购买了恩安达制药的新股份，价值约为 5,968,000 美元。Marshall Wace LLP 在第四季度将其在恩安达制药的持股增加了 9.3%。Marshall Wace LLP 现在拥有 930,087 股该生物技术公司的股票，价值 5,348,000 美元，此前在上个季度又购买了 79,197 股。Millennium Management LLC 在第四季度将其在恩安达制药的持股增加了 22.7%。Millennium Management LLC 现在拥有 896,987 股该生物技术公司的股票，价值 5,158,000 美元，此前在上个季度又购买了 165,692 股。最后，Geode Capital Management LLC 在第三季度将其在恩安达制药的持股增加了 3.1%。Geode Capital Management LLC 现在拥有 477,351 股该生物技术公司的股票，价值 4,946,000 美元，此前在上个季度又购买了 14,575 股。94.99% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Enanta Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>恩安达制药股票表现</h2>
</div><p>Shares of NASDAQ ENTA opened at $4.73 on Friday. The firm has a market cap of $100.91 million, a P/E ratio of -0.96 and a beta of 0.47. Enanta Pharmaceuticals has a 1 year low of $4.52 and a 1 year high of $17.24. The firm's 50 day moving average price is $6.39 and its 200 day moving average price is $8.00.</p>
<div class="lb-trans"><p>恩安达制药（NASDAQ:ENTA - 获取免费报告）股票在周五开盘时为 4.73 美元。该公司的市值为 1.0091 亿美元，市盈率为-0.96，贝塔值为 0.47。恩安达制药的 1 年最低价为 4.52 美元，1 年最高价为 17.24 美元。该公司的 50 日移动平均价格为 6.39 美元，200 日移动平均价格为 8.00 美元。</p>
</div><p>Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. As a group, equities analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current year.</p>
<div class="lb-trans"><p>恩安达制药（NASDAQ:ENTA - 获取免费报告）最近于 2 月 10 日星期一发布了季度财报。这家生物技术公司报告的每股收益（EPS）为-1.05 美元，超过了市场共识预期的-1.16 美元，超出幅度为 0.11 美元。恩安达制药的股本回报率为-75.53%，净利润率为-157.57%。整体来看，股票分析师预测恩安达制药在本年度将发布-4.65 的每股收益。</p>
</div><h2>About Enanta Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于恩安达制药</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.</p>
<div class="lb-trans"><p>恩安达制药公司是一家生物技术公司，专注于发现和开发用于治疗病毒感染和肝病的小分子药物。其产品管线包括 EDP-514，目前正在进行针对慢性乙型肝炎病毒（HBV）感染的 1b 期临床开发；EDP-938 和 EDP-323，目前正在进行针对呼吸道合胞病毒的 II 期临床开发；EDP-235，目前正在进行针对人类冠状病毒的 II 期临床开发；以及 Glecaprevir，目前已上市用于治疗慢性丙型肝炎病毒（HCV）感染。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Enanta Pharmaceuticals</li>
<li>Quiet Period Expirations Explained</li>
<li>Archer Aviation’s Africa Deal Could Boost ACHR Stock</li>
<li>Natural Gas Prices Continue To Rally, These Stocks Should Benefit</li>
<li>Are Short Sellers Wrong About These 3 Semiconductor Stocks?</li>
<li>The 3 Best Retail Stocks to Shop for in August</li>
<li>Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比恩安达制药更好</li>
<li>安静期到期的解释</li>
<li>Archer Aviation 在非洲的交易可能会提升 ACHR 股票</li>
<li>天然气价格继续上涨，这些股票将受益</li>
<li>空头卖家对这三只半导体股票是否错误？</li>
<li>八月值得购买的三只最佳零售股票</li>
<li>波音在三月份获得 500 亿美元订单——BA 股票现在值得买吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ENTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Enanta Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在恩安达制药吗？</h2>
</div><p>Before you consider Enanta Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑恩安达制药之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而恩安达制药并不在名单上。</p>
</div><p>While Enanta Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Enanta 制药目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Enanta 制药公司（纳斯达克股票代码：ENTA）获得券商的 “适度买入” 平均推荐